mitoxantrone has been researched along with Cardiac Failure in 46 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography." | 9.12 | Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. ( Bernitsas, E; Mikol, DD; Wei, W, 2006) |
| "Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS)." | 8.90 | [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis]. ( Szwed, M, 2014) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 8.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 7.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 7.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Mitoxantrone is an immunosuppressive drug usually delivered in severe relapsing remitting multiple sclerosis." | 7.72 | [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis]. ( Ali Chérif, A; Eusebio, A; Feuillet, L; Guedj, E; Malikova, I; Mundler, O; Pelletier, J, 2003) |
| "Fifteen women with metastatic breast cancer undergoing autologous bone marrow transplantation were treated with an intensive induction regimen including cyclophosphamide and mitoxantrone in a phase I-II study." | 7.68 | Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer. ( Hooker, JL; Lewkow, LM; Movahed, A, 1992) |
| "Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i." | 7.67 | Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. ( Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984) |
| "Two children, who had received chemotherapy with doxorubicin and cisplatin for disseminated chondrosarcoma and recurrent rhabdomyosarcoma, developed congestive heart failure following treatment with mitoxantrone (DHAD); the total doses of DHAD were 128 and 90 mg/m2, respectively." | 7.66 | Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. ( Crom, DB; Miliauskas, J; Pratt, CB; Sanyal, SK; Sohlberg, K; Wallenberg, J, 1983) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 6.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Leukopenia is similar with the three drugs." | 6.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Half of our patients presenting with breast cancer will eventually require cytotoxic chemotherapy." | 6.65 | Mitoxantrone treatment in advanced breast cancer. ( Andrews, J; Cheng, ZM; Collins, J; Leyden, M; Russell, I; Sullivan, J, 1984) |
| "Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US)." | 5.17 | Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. ( Bock, D; Dangond, F; Jeffery, DR; Rivera, VM; Weinstock-Guttman, B, 2013) |
| "An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography." | 5.12 | Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. ( Bernitsas, E; Mikol, DD; Wei, W, 2006) |
| "Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS)." | 4.90 | [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis]. ( Szwed, M, 2014) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 4.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "High-dose mitoxantrone therapy is associated with an excellent remission rate but with a significantly increased risk of clinical and subclinical early cardiotoxicity and heart failure." | 3.83 | Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis. ( Ahmed, M; Aurigemma, GP; Cerny, J; Escobar, J; Kane, JL; McGuiness, ME; McManus, DD; Meyer, TE; Nath, R; Ramanathan, M; Shaikh, AY; Shih, J; Suryadevara, S; Tighe, DA; Tripathi, A, 2016) |
| "Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS)." | 3.80 | The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. ( Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014) |
| "Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS)." | 3.73 | Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. ( Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005) |
| "Mitoxantrone is an immunosuppressive drug usually delivered in severe relapsing remitting multiple sclerosis." | 3.72 | [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis]. ( Ali Chérif, A; Eusebio, A; Feuillet, L; Guedj, E; Malikova, I; Mundler, O; Pelletier, J, 2003) |
| " Immunoblot analysis revealed iNOS protein expression in four out of six failing hearts from septic patients, whereas no iNOS-protein expression was detected in either non-failing human hearts (n = 6) or failing hearts due to IDC (n = 9), ischemic heart disease (IHD, n = 7), Becker muscular dystrophy (BMD, n = 2) and mitoxantrone-induced toxic cardiomyopathy TCM, n = 1)." | 3.69 | Expression of inducible nitric oxide synthase in failing and non-failing human heart. ( Bleese, NM; Förstermann, U; Nüssler, AK; Scholz, H; Stein, B; Thoenes, M; Tracey, WR, 1996) |
| "Fifteen women with metastatic breast cancer undergoing autologous bone marrow transplantation were treated with an intensive induction regimen including cyclophosphamide and mitoxantrone in a phase I-II study." | 3.68 | Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer. ( Hooker, JL; Lewkow, LM; Movahed, A, 1992) |
| "Thirty-four patients with advanced breast cancer, who had not received previous chemotherapy for metastatic disease, were treated with mitoxantrone 14 mg/m2 i." | 3.67 | Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. ( Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984) |
| " Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone." | 3.67 | [Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. ( Hattori, M; Honda, T; Sampi, K, 1984) |
| "Two children, who had received chemotherapy with doxorubicin and cisplatin for disseminated chondrosarcoma and recurrent rhabdomyosarcoma, developed congestive heart failure following treatment with mitoxantrone (DHAD); the total doses of DHAD were 128 and 90 mg/m2, respectively." | 3.66 | Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin. ( Crom, DB; Miliauskas, J; Pratt, CB; Sanyal, SK; Sohlberg, K; Wallenberg, J, 1983) |
| "Mitoxantrone is an antineoplastic drug, recently approved for treatment of multiple sclerosis." | 2.72 | Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. ( Etemadifar, M; Hamzehloo, A, 2006) |
| "67 patients with relapsed or resistant multiple myeloma were randomized to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone)." | 2.68 | A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. ( Cawley, JC; Davies, JM; Newland, AC; Pearce, R; Phillips, JK; Reilly, JT; Sherlaw-Johnson, C, 1995) |
| "38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone." | 2.67 | A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
| "Leukopenia is similar with the three drugs." | 2.66 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). ( Constanzi, JJ; Cowan, JD; Neidhart, JA; Osborne, CK; Vaughn, CB; Von Hoff, DD, 1985) |
| "Half of our patients presenting with breast cancer will eventually require cytotoxic chemotherapy." | 2.65 | Mitoxantrone treatment in advanced breast cancer. ( Andrews, J; Cheng, ZM; Collins, J; Leyden, M; Russell, I; Sullivan, J, 1984) |
| "No patients experienced congestive heart failure (CHF) before treatment." | 2.41 | Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. ( Butine, MD; Edan, G; Eisenman, S; Ghalie, RG; Gonsette, RE; Goodkin, DE; Hartung, HP; Laurent, M; Mauch, E, 2002) |
| "Twelve years after the diagnosis of acute myeloid leukemia, and following a viral infection of an unknown cause, he developed symptoms of heart failure." | 1.36 | Heart transplant in a childhood leukemia survivor: a case report. ( Bubanska, E; Hrebik, M; Mladosievicova, B; Urbanova, D, 2010) |
| "However, cardiac failure, the primary cause of death in four patients, was associated with coagulative fiber necroses and contraction band necroses, which may be related to acute cyclophosphamide toxicity." | 1.27 | Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor. ( Dörken, B; Körbling, M; Mall, G; von Herbay, A, 1988) |
| "Mitoxantrone is a synthetic anthraquinone that was developed through the doxorubicin analog program in hopes of retaining anticancer activity with less cardiotoxicity." | 1.27 | Cardiac evaluation of mitoxantrone. ( Balcerzak, SP; Bashore, TA; Neidhart, JA; Unverferth, BJ; Unverferth, DV, 1983) |
| "Two percent had congestive heart failure associated with doxorubicin." | 1.27 | Early and delayed clinical cardiotoxicity of doxorubicin. ( Blumenschein, GR; Buzdar, AU; Marcus, C; Smith, TL, 1985) |
| "All but one had breast cancer, 29 had received prior doxorubicin and 29 of the 37 patients who had not had prior doxorubicin received it or another anthracycline subsequently." | 1.27 | Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. ( Benjamin, RS; Carrasco, CH; Chawla, SP; Ewer, MS; Holmes, F; Mackay, B, 1985) |
| "Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were tested with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface area daily for 5 consecutive days every 4 weeks." | 1.26 | Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Schell, FC; Valdivieso, M; Yap, HY, 1981) |
| "Mitoxantrone is a promising new agent developed in an attempt to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity." | 1.26 | Potential cardiotoxicity with mitoxantrone. ( Blumenschein, G; Bodey, G; Schell, FC; Valdivieso, M; Yap, HY, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (39.13) | 18.7374 |
| 1990's | 10 (21.74) | 18.2507 |
| 2000's | 10 (21.74) | 29.6817 |
| 2010's | 8 (17.39) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rivera, VM | 1 |
| Jeffery, DR | 1 |
| Weinstock-Guttman, B | 1 |
| Bock, D | 1 |
| Dangond, F | 1 |
| Szwed, M | 1 |
| Podlecka-Piętowska, A | 1 |
| Kochanowski, J | 1 |
| Zakrzewska-Pniewska, B | 1 |
| Opolski, G | 1 |
| Kwieciński, H | 1 |
| Kamińska, AM | 1 |
| Shaikh, AY | 1 |
| Suryadevara, S | 1 |
| Tripathi, A | 1 |
| Ahmed, M | 1 |
| Kane, JL | 1 |
| Escobar, J | 1 |
| Cerny, J | 1 |
| Nath, R | 1 |
| McManus, DD | 1 |
| Shih, J | 1 |
| McGuiness, ME | 1 |
| Tighe, DA | 1 |
| Meyer, TE | 1 |
| Ramanathan, M | 1 |
| Aurigemma, GP | 1 |
| Dörr, J | 2 |
| Bitsch, A | 1 |
| Schmailzl, KJ | 1 |
| Chan, A | 1 |
| von Ahsen, N | 1 |
| Hummel, M | 1 |
| Varon, R | 1 |
| Lill, CM | 1 |
| Vogel, HP | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Urbanova, D | 1 |
| Bubanska, E | 1 |
| Hrebik, M | 1 |
| Mladosievicova, B | 1 |
| Killestein, J | 1 |
| van der Meer, ML | 1 |
| Regelink, JC | 1 |
| Huijgens, PC | 1 |
| Polman, CH | 1 |
| Le Page, E | 1 |
| Leray, E | 1 |
| Edan, G | 2 |
| Staib, P | 1 |
| Forsch, S | 1 |
| Niedeggen, A | 1 |
| Janssens, U | 1 |
| Ghalie, RG | 1 |
| Laurent, M | 1 |
| Mauch, E | 1 |
| Eisenman, S | 1 |
| Hartung, HP | 1 |
| Gonsette, RE | 1 |
| Butine, MD | 1 |
| Goodkin, DE | 1 |
| Casarotto, D | 1 |
| Bottio, T | 1 |
| Gambino, A | 1 |
| Testolin, L | 1 |
| Gerosa, G | 1 |
| Gbadamosi, J | 1 |
| Münchau, A | 1 |
| Weiller, C | 1 |
| Schäfer, H | 1 |
| Feuillet, L | 1 |
| Guedj, E | 1 |
| Eusebio, A | 1 |
| Malikova, I | 1 |
| Pelletier, J | 1 |
| Mundler, O | 1 |
| Ali Chérif, A | 1 |
| Cohen, BA | 1 |
| Mikol, DD | 2 |
| Goffette, S | 1 |
| van Pesch, V | 1 |
| Vanoverschelde, JL | 1 |
| Morandini, E | 1 |
| Sindic, CJ | 1 |
| Bernitsas, E | 1 |
| Wei, W | 1 |
| Pratt, RG | 1 |
| Boehm, GA | 1 |
| Kortepeter, CM | 1 |
| Racoosin, JA | 1 |
| Hamzehloo, A | 1 |
| Etemadifar, M | 1 |
| Stuart-Harris, R | 1 |
| Pearson, M | 1 |
| Smith, IE | 2 |
| Olsen, EG | 1 |
| Sampi, K | 1 |
| Honda, T | 1 |
| Hattori, M | 1 |
| Crossley, RJ | 1 |
| Leyden, M | 1 |
| Cheng, ZM | 1 |
| Collins, J | 1 |
| Russell, I | 1 |
| Andrews, J | 1 |
| Sullivan, J | 1 |
| Coleman, RE | 1 |
| Maisey, MN | 1 |
| Knight, RK | 1 |
| Rubens, RD | 1 |
| Smalley, R | 1 |
| Gams, R | 1 |
| Pratt, CB | 1 |
| Crom, DB | 1 |
| Wallenberg, J | 1 |
| Sanyal, SK | 1 |
| Miliauskas, J | 1 |
| Sohlberg, K | 1 |
| Unverferth, DV | 1 |
| Unverferth, BJ | 1 |
| Balcerzak, SP | 2 |
| Bashore, TA | 1 |
| Neidhart, JA | 2 |
| Schell, FC | 2 |
| Yap, HY | 2 |
| Blumenschein, G | 1 |
| Valdivieso, M | 2 |
| Bodey, G | 1 |
| Blumenschein, GR | 2 |
| Buzdar, AU | 2 |
| Bodey, GP | 1 |
| Phillips, JK | 1 |
| Sherlaw-Johnson, C | 1 |
| Pearce, R | 1 |
| Davies, JM | 1 |
| Reilly, JT | 1 |
| Newland, AC | 1 |
| Cawley, JC | 1 |
| Benjamin, RS | 2 |
| Bezwoda, WR | 1 |
| Bezwoda, MA | 1 |
| Seymour, L | 1 |
| Dansey, R | 1 |
| Ariad, S | 1 |
| Okamoto, M | 1 |
| Miyazaki, H | 1 |
| Tsuzuki, M | 1 |
| Ino, T | 1 |
| Ezaki, K | 1 |
| Hirano, M | 1 |
| Thoenes, M | 1 |
| Förstermann, U | 1 |
| Tracey, WR | 1 |
| Bleese, NM | 1 |
| Nüssler, AK | 1 |
| Scholz, H | 1 |
| Stein, B | 1 |
| Kahles, H | 1 |
| Bastian, HJ | 1 |
| Schiffmann, O | 1 |
| Geck, M | 1 |
| Helmke, FR | 1 |
| Golz, N | 1 |
| Aitini, E | 1 |
| Cavazzini, G | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Rivera, A | 1 |
| Togliani, B | 1 |
| Di Marco, A | 1 |
| Smerieri, F | 1 |
| Lewkow, LM | 1 |
| Hooker, JL | 1 |
| Movahed, A | 1 |
| Carrió, I | 1 |
| Estorch, M | 1 |
| Berná, L | 1 |
| Germá, JR | 1 |
| Alonso, C | 1 |
| Ojeda, B | 1 |
| de Andrés, L | 1 |
| Lopez-Pousa, A | 1 |
| Martinez-Duncker, C | 1 |
| Torres, G | 1 |
| Ellis, ED | 1 |
| Williams, SF | 1 |
| Moormeier, JA | 1 |
| Kaminer, LS | 1 |
| Bitran, JD | 1 |
| Janmohammed, R | 1 |
| Milligan, DW | 1 |
| von Herbay, A | 1 |
| Dörken, B | 1 |
| Mall, G | 1 |
| Körbling, M | 1 |
| Bull, FE | 1 |
| Von Hoff, DD | 2 |
| Stephens, RL | 1 |
| Panettiere, FJ | 1 |
| Posner, LE | 1 |
| Dukart, G | 1 |
| Goldberg, J | 1 |
| Bernstein, T | 1 |
| Cartwright, K | 1 |
| Cowan, JD | 1 |
| Osborne, CK | 1 |
| Constanzi, JJ | 1 |
| Vaughn, CB | 1 |
| Marcus, C | 1 |
| Smith, TL | 1 |
| Chawla, SP | 1 |
| Ewer, MS | 1 |
| Carrasco, CH | 1 |
| Mackay, B | 1 |
| Holmes, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for mitoxantrone and Cardiac Failure
| Article | Year |
|---|---|
[Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Axons; Cell Death; Heart Failure; Humans; Mitoxantrone | 2014 |
Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.
Topics: Adolescent; Adult; Age Factors; Aged; Chi-Square Distribution; Confidence Intervals; Drug Administra | 2002 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Animals; Cardiomyopathies; Drug Monitoring; Heart Failure; Humans; Immunosuppressive Agents; Leukemi | 2004 |
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
Rationale for the use of mitoxantrone in the older patient: cardiac toxicity.
Topics: Age Factors; Aged; Biopsy; Breast Neoplasms; Doxorubicin; Heart Failure; Humans; Mitoxantrone; Myoca | 1995 |
13 trials available for mitoxantrone and Cardiac Failure
| Article | Year |
|---|---|
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Topics: Adult; Aged; Female; Heart Failure; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Scle | 2013 |
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.
Topics: Adult; Animals; Antineoplastic Agents; Cardiovascular Agents; Female; Heart Failure; Humans; Male; M | 2006 |
Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Topics: Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Echocardiography; Electrocardiograph | 2006 |
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
Clinical safety and tolerance of mitoxantrone (Novantrone).
Topics: Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Depr | 1983 |
Mitoxantrone treatment in advanced breast cancer.
Topics: Adult; Aged; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Female; Heart Failure; Huma | 1984 |
A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance; F | 1995 |
NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Heart Failure; Humans; Lymphoma, | 1993 |
A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1992 |
A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies.
Topics: Actuarial Analysis; Chicago; Cyclophosphamide; Drug Evaluation; Heart Failure; Hematopoietic Stem Ce | 1990 |
Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as T | 1985 |
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Topics: Adult; Aged; Alopecia; Anthracenes; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinica | 1985 |
29 other studies available for mitoxantrone and Cardiac Failure
| Article | Year |
|---|---|
The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients.
Topics: Adult; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Female; Heart Diseases; Heart Failure; H | 2014 |
Mitoxantrone-Induced Cardiotoxicity in Acute Myeloid Leukemia-A Velocity Vector Imaging Analysis.
Topics: Aged; Antineoplastic Agents; Causality; Comorbidity; Echocardiography; Elasticity Imaging Techniques | 2016 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tr | 2009 |
Heart transplant in a childhood leukemia survivor: a case report.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Daunorubicin; Heart F | 2010 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Antineoplastic Agents; Female; Heart Failure; Humans; Middle Aged; Mitoxantrone; Multiple Sclerosis; | 2010 |
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Topics: Adult; Amenorrhea; Female; France; Heart Failure; Humans; Immunologic Factors; Leukemia; Male; Middl | 2011 |
[Percutaneous coronary intervention in a patient with acute myeloid leukemia].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; | 2012 |
The last to die is hope: prolonged mechanical circulatory support with a Novacor left ventricular assist device as a bridge to transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cardiomyopathy, Dilated; Castleman Di | 2003 |
Severe heart failure in a young multiple sclerosis patient.
Topics: Adult; Antineoplastic Agents; Drug Overdose; Heart Failure; Humans; Male; Mitoxantrone; Multiple Scl | 2003 |
[Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis].
Topics: Acute Disease; Female; Heart Failure; Humans; Middle Aged; Mitoxantrone; Multiple Sclerosis | 2003 |
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Topics: Adult; Cohort Studies; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Mitoxant | 2005 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Analgesics; Cardiomyopathies; Dose-Response Relationship, Drug; Drug-Related Side Effects and Advers | 2005 |
Cardiotoxicity associated with mitoxantrone.
Topics: Anthraquinones; Antineoplastic Agents; Heart Failure; Humans; Mitoxantrone | 1984 |
[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report].
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 1984 |
Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Heart | 1984 |
Phase II study of mitoxantrone in patients with metastatic breast carcinoma: a Southeastern Cancer Study Group project.
Topics: Adult; Anthraquinones; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; | 1983 |
Fatal congestive heart failure following mitoxantrone treatment in two children previously treated with doxorubicin and cisplatin.
Topics: Anthraquinones; Child; Child, Preschool; Chondrosarcoma; Cisplatin; Doxorubicin; Female; Heart; Hear | 1983 |
Cardiac evaluation of mitoxantrone.
Topics: Aged; Anthraquinones; Antineoplastic Agents; Biopsy; Female; Heart Failure; Heart Function Tests; Hu | 1983 |
Potential cardiotoxicity with mitoxantrone.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Heart | 1982 |
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthracenes; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Dru | 1981 |
[Long-term selective beta 1-blockade therapy for a patient with anthracycline-induced cardiomyopathy].
Topics: Aclarubicin; Adrenergic beta-Antagonists; Adult; Antibiotics, Antineoplastic; Cardiomyopathy, Hypert | 1995 |
Expression of inducible nitric oxide synthase in failing and non-failing human heart.
Topics: Animals; Cardiomyopathies; Cardiomyopathy, Dilated; Cell Line; Cyclic GMP; Gene Expression; Heart Fa | 1996 |
[Mitoxantrone-induced acute left heart failure after intrapleural administration].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Dose-R | 1997 |
Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1992 |
Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies.
Topics: Adult; Aged; Breast Neoplasms; Doxorubicin; Female; Heart; Heart Failure; Humans; Indium Radioisotop | 1991 |
Mitoxantrone induced congestive heart failure in patients previously treated with anthracyclines.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Female; Heart Failure; Humans; Leukemia, | 1989 |
Cardiac damage in autologous bone marrow transplant patients: an autopsy study. Cardiotoxic pretreatment as a major risk factor.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Transplantation; Cardiomyopat | 1988 |
Early and delayed clinical cardiotoxicity of doxorubicin.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathies; Cyclo | 1985 |
Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.
Topics: Adult; Aged; Angiocardiography; Anthraquinones; Antineoplastic Agents; Biopsy; Breast Neoplasms; Dox | 1985 |